Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
PHASE4
Hemophilia A is a blood coagulation disorder caused by deficient or dysfunc...
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
PHASE3
The primary objectives of this study are: to evaluate the safety and tolera...
Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
N/A
Haemophilia A and haemophilia B are inherited bleeding disorders resulting ...
Status
Unknown
Location
Centre de Référence en Hémophilie, hôpityal Louis Pradel, GHE- Hospices Civils de Lyon